which glp 1 is approved for sleep apnea Zepbound's New FDA Approval: What It Means Treating Moderate to Severe Survey: Providers Want GLP-1s Approved

Conclusion The GLP-1 RAs in people with obesity or type 2 diabetes are associated with a significant reduction in all-cause death, alongside an increased risk of pancreatic adverse eventsparticularly acute pancreatitismost pronounced during the first 6 months of treatment

The class includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro, a dual GLP-1/GIP receptor agonist), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and lixisenatide (Adlyxin)

Symptoms of abdominal pain, constipation, diarrhea, nausea and vomiting are well-known adverse events for glucagon-like peptide-1 receptor agonists (GLP-1s), often related to delayed gastric emptying

Shine B, McKnight RF, Leaver L, Geddes JR

With patient access to affordable GLP-1s on the line, the FDA has a difficult decision to make

Overall, the data revealed that abnormal thyroid function may occur during and in the convalescence post-COVID condition phase